oral semaglutide cardiovascular outcomes soul trial results 2024 2025 A emulation in Nature Medicine shows that treatment with and tirzepatide showed similar levels of benefit on in people at elevated cardiovascular risk with obesity and diabetes. Link Frontiers | Cardiovascular Safety and

Our medical, nutrition, and metabolic professional expertise adds value to the Feel Beautiful Plastic Surgery weight loss program

But I do think theres a place for orals in the market, both clinically and just efficacy-wise. The challenge, Verbeke explains, is in targeting the right patient population, particularly those for whom moderate weight loss and convenience may outweigh the maximal clinical effect

Your choice should depend on whether you are more concerned about missing a dose or potentially experiencing a slight increase in nausea

Why do We Use Semaglutide Obesity is a chronic disease with a neurobiological basis the hypothalamic and reward system dysregulation that drives excess caloric intake and fat accumulation isn't a character defect, and it doesn't respond reliably to willpower-based interventions alone